Fig. 6: Analysis of the menin-HIF axis in human endometrial cancers and the effect of MI-136 on the growth of patient-derived endometrial cancer organoids. | Cancer Gene Therapy

Fig. 6: Analysis of the menin-HIF axis in human endometrial cancers and the effect of MI-136 on the growth of patient-derived endometrial cancer organoids.

From: An organoid-based drug screening identified a menin-MLL inhibitor for endometrial cancer through regulating the HIF pathway

Fig. 6

a The expression levels of MEN1 and HIF1A in human normal endometrium (n = 35) and endometrial cancers (n = 587), analyzed from The Cancer Genome Atlas. b The correlation of MEN1 and HIF1A expressions in human endometrial cancers. c Kaplan–Meier relapse free survival curve of endometrial cancer patients with low or high expressions of MEN1. Patients were split by median on the basis of MEN1 mRNA expression. d Kaplan–Meier overall survival curve of endometrial cancer patients with low or high expressions of MEN1. Patients were split by median on the basis of MEN1 mRNA expression. e–h Relative cell viability and organoid numbers of Patient 1–4 tumor organoids treated with MI-136, comparing to those of vehicle. Error bars represent SD. *p < 0.05; **p < 0.01; ***p < 0.001.

Back to article page